Open letter to WHO & ACT-A: We need affordable treatments for the rise of serious invasive fungal diseases that are life-threatening for COVID-19 survivors and HIV+ people

MSF and others sent this open letter to the World Health Organization (WHO) and the Access to COVID-19 Tools Accelerator (ACT-A) about the urgent need for liposomal amphotericin B (L-AmB) and other drugs for the treatment of severe fungal infections, including mucormycosis (“black fungus”), a COVID-19-related complication that has claimed the lives of more than 10,000 people to date, and severely disfigured many more, in India and Nepal. L-AmB is also a crucial treatment for cryptococcal meningitis, visceral leishmaniasis (kala azar), and other fungal infections.